DVAX

Dynavax Technologies Corporation [DVAX] Stock Forecast

Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
RSI : 000

DVAX Stock Summary

Top 10 Correlated Stocks

DVAX

In the News

DVAX Financial details

Company Rating
-
Market Cap
1.55B
Income
-6.39M
Revenue
232.28M
Book val./share
-
Cash/share
-
Dividend
-
Dividend %
-
Employees
408
Optionable
No
Shortable
Yes
Earnings
30 Apr 2024
P/E
-244.02
Forward P/E
-
PEG
23.87
P/S
6.78
P/B
2.51
P/C
-
P/FCF
16.32
Quick Ratio
12.65
Current Ratio
13.81
Debt / Equity
-
LT Debt / Equity
-
-
-
EPS (TTM)
-0.05
EPS next Y
-
EPS next Q
-
EPS this Y
-102.14%
EPS next Y
-
EPS next 5Y
-
EPS last 5Y
-52.72%
Revenue last 5Y
45.83%
Revenue Q/Q
-20.02%
EPS Q/Q
-98.45%
-
-
-
-
SMA20
4.41%
SMA50
-23.8%
SMA100
-18.63%
Inst Own
-
Inst Trans
-
ROA
-1%
ROE
-1%
ROC
-0.03%
Gross Margin
78%
Oper. Margin
-11%
Profit Margin
-3%
Payout
-
Shs Outstand
-
Shs Float
-
-
-
-
-
Target Price
-
52W Range
10.06-15.15
52W High
-31.53%
52W Low
+2.7%
RSI
50.72
Rel Volume
0.56
Avg Volume
1.91M
Volume
1.06M
Perf Week
3.84%
Perf Month
-10.54%
Perf Quarter
-19.58%
Perf Half Y
-20.45%
-
-
-
-
Beta
1.282
-
-
Volatility
0.15%, 0.48%
Prev Close
-1.25%
Price
10.27
Change
1.99%

Something similar

Top by Market Cap
LLY.DE
V
FXAIX
GOOG
CMC.DE
Same Sector
PRVB
002437.SZ
002030.SZ
2196.HK
4502.T
Top Correlated Stocks
MYGN
TMRAY
0K3W.L
APLS
CYTK
Similar Market Cap
G2X.DE
PAR
9906.HK
SNPE
JPYRX

Company Profile

Healthcare Drug Manufacturers - Specialty & Generic
  • Volume Average 1.91M
  • Market Capitalization 1.55B
  • Employee 408
  • CEO Mr. Ryan Spencer
  • Headquarters EmeryVille,CA,US
  • IPO Date 2004-02-19
  • Website https://www.dynavax.com

Dynavax Technologies Corporation, a biopharmaceutical company, focuses on developing and commercializing novel vaccines in the United States. The company markets HEPLISAV-B, a hepatitis B vaccine for prevention of infection caused by all known subtypes of hepatitis B virus in age 18 years and older in the United States and Europe. It also manufactures and sells CpG 1018, the adjuvant used in HEPLISAV-B. Dynavax Technologies Corporation has a collaboration agreement with Valneva Scotland Limited; agreement with Serum Institute of India Pvt. Ltd.; and sublicense agreement with Merck, Sharp & Dohme Corp. The company was formerly known as Double Helix Corporation and changed its name to Dynavax Technologies Corporation in September 1996. Dynavax Technologies Corporation was incorporated in 1996 and is headquartered in Emeryville, California.